ELCC 2022 – Jarushka Naidoo
Jarushka Naidoo depicts recent developments in the first-line therapy of limited-stage small cell lung cancer (SCLC), treatment options for patients with newly diagnosed extensive-stage SCLC, agents emerging for the management of patients with platinum-refractory disease, the molecular types of SCLC and how they respond to targeted therapies and ICIs and gives an overview of the greatest difficulties in the field of irAEs.